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ARTICLE
Muscular dystrophy with marked Dysferlin deﬁciency
is consistently caused by primary dysferlin gene
mutations
Mafalda Cacciottolo1,7, Gelsomina Numitone1,7, Stefania Aurino1, Imma Rosaria Caserta1, Marina Fanin2,
Luisa Politano3, Carlo Minetti4, Enzo Ricci5, Giulio Piluso6, Corrado Angelini2 and Vincenzo Nigro*,1,6
Dysferlin is a 237-kDa transmembrane protein involved in calcium-mediated sarcolemma resealing. Dysferlin gene mutations
cause limb-girdle muscular dystrophy (LGMD) 2B, Miyoshi myopathy (MM) and distal myopathy of the anterior tibialis.
Considering that a secondary Dysferlin reduction has also been described in other myopathies, our original goal was to identify
cases with a Dysferlin deﬁciency without dysferlin gene mutations. The dysferlin gene is huge, composed of 55 exons that span
233140bp of genomic DNA. We performed a thorough mutation analysis in 65 LGMD/MM patients with r20% Dysferlin. The
screening was exhaustive, as we sequenced both genomic DNA and cDNA. When required, we used other methods, including
real-time PCR, long PCR and array CGH. In all patients, we were able to recognize the primary involvement of the dysferlin gene.
We identiﬁed 38 novel mutation types. Some of these, such as a dysferlin gene duplication, could have been missed by
conventional screening strategies. Nonsense-mediated mRNA decay was evident in six cases, in three of which both alleles were
only detectable in the genomic DNA but not in the mRNA. Among a wide spectrum of novel gene defects, we found the ﬁrst
example of a ‘nonstop’ mutation causing a dysferlinopathy. This study presents the ﬁrst direct and conclusive evidence that an
amount of Dysferlin r20% is pathogenic and always caused by primary dysferlin gene mutations. This demonstrates the high
speciﬁcity of a marked reduction of Dysferlin on western blot and the value of a comprehensive molecular approach for
LGMD2B/MM diagnosis.
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INTRODUCTION
Mutations in the dysferlin gene are responsible for three main
dystrophic phenotypes: limb-girdle muscular dystrophy type 2B
(LGMD2B; MIM# 2536011,2), Miyoshi myopathy (MM; MIM#
2541302) and distal myopathy with anterior tibialis onset (DMAT;
MIM# 606768.3). During the course of the disease, the phenotypes
show a substantial amount of overlap with weakness extending from
the proximal to distal muscles and vice versa.4,5 Even if clinical
differences are reported, they may not be so striking at the pathological
level.6 A unique ﬁnding within the spectrum of muscular dystrophies is
that the majority of Dysferlin-deﬁcient patients appear to have no initial
muscle weakness. Indeed, they often show a good performance at sport
or have jobs that require physical activity, suggesting that exercise may
be a disease-triggering factor.7,8 A secondary Dysferlin reduction has
also been observed in calpain-3 (LGMD2A9)a n dc a v e o l i n - 3
(LGMD1C10). A similar phenotype has also been described in patients
with anoctamin-5 gene (LGMD2L11) mutations.
The dysferlin gene is huge and routine mutation detection is a long
and expensive process. In addition, there are no prevalent mutations,
but, instead, 415 different allelic variants have been identiﬁed thus
far (http://www.dmd.nl). The cost-effectiveness of a dysferlin gene
mutation screening using DHPLC approaches has been reported in
large groups of patients with the identiﬁcation of many mutations,
therefore validating the efﬁcacy of genomic mutational screening for
routine diagnosis.12
Most authors have been able to identify the majority of dysferlin gene
mutations (but not all) when Dysferlin was absent from the muscle.13,14
Several mutational screenings have been reported, many of them based
on isolated cases/families and the identiﬁcation of private mutations.15–22
The biggest cohort was analysed by Krahn et al,12 composed of 134
patients, including a group that had previously been described.18 The
authors identiﬁed at least one pathological allele in 119/134 patients
(88%). The success rate was higher than that in other LGMD cases,23 but
not all cases were solved, indicating either that other genes causing
secondary defects of Dysferlin are rarer, or that the mutation analyses
have been inaccurate in that they have missed some of the defects.
Our original aim was to focus on LGMD cases with a marked
Dysferlin reduction and no mutation. To achieve this objective, we
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of 65 LGMD/MM patients with a marked reduction or absence of the
protein detected by western blot. We used all available screening methods
starting from genomic DNA and mRNA. Here we show the high
speciﬁcity of the absence or marked reduction of dysferlin expression
on muscle biopsy and the high speciﬁcity and sensitivity of a compre-
hensive molecular approach in the diagnosis of LGMD2B/MM.
PATIENTS AND METHODS
Patient recruitment
The patients were between 26 and 77 years of age. They had serum levels of
creatine kinase between 1200 and 8000U/L (with an average value of
3507U/L). These patients showed an absence or marked reduction (5–20%
of the normal amount) of Dysferlin in their skeletal muscle. A total of 10 out of
65 were affected by Miyoshi myopathy, whereas the remaining 55 had an
LGMD2B phenotype. In our study we analysed eight pairs of siblings. Only
three of these patients are wheelchair-conﬁned in accordance with the slow
progression rate of the dysferlinopathies. In particular, the age at which they
began to use a wheelchair was very variable (22, 39 and 49 years of age,
respectively), again in accordance with the phenotypical variability of the
dysferlinopathies.5,24,25
Biological samples were obtained from 65 patients (61 of whom were
Italians) from different centres: Naples (16/65), Rome (5/65), Genoa (8/65),
Padua (31/65), Ankara (Turkey; 3/65) and Buenos Aires (Argentina; 1/65). For
all these patients genomic DNA and/or mRNA from blood samples or muscle
biopsies were available.
Muscle biopsy
At the time of diagnosis, an open biopsy from the quadriceps femoris muscle
was obtained under local anaesthesia after written informed consent.
Muscle biopsy specimens were frozen in isopentane, cooled in liquid
nitrogen and stored at 801C until processed.
Multiple western blot analysis of muscle proteins and
quantiﬁcation
Western blot (WB) analysis and detailed protein analyses were performed
as previously described,26 using a mixture of monoclonal antibodies
against Calpain-3 (Calp12A2, diluted 1:800), a-Sarcoglycan (diluted 1:300),
b-Sarcoglycan (diluted 1:300), Dystrophin (Dys-2, diluted 1:1000) and
Dysferlin (Hamlet, diluted 1:1000), all purchased from Novocastra (Newcastle,
UK). In brief, the quantity of muscle proteins in the samples from the controls
and patients was determined by densitometry using ImageJ software v.1.34n
(Image Software Services, Shirley, MA, USA) and normalized to the amount of
tissue loaded in each lane, using the skeletal myosin bands in the post-transfer
Coomassie blue-stained gels. The values in each patient were expressed as
percentages of the mean of the controls.
PCR conditions from gDNA
The dysferlin gene (NM_001130987.1, 55 coding exons) was ampliﬁed by PCR
from genomic DNA. All the exons and ﬂanking intron sequences were
ampliﬁed using speciﬁc primer pairs (Supplementary Table S1). In a ﬁnal
volume of 25ml, 60–75ng of genomic DNA was combined with 0.6mM of each
primer, 0.6mM all dNTPs, buffer LB1X (20mM Tris, 10 mM Hepes, 2.5mM
magnesium sulfate, 10mM potassium chloride and 10mM ammonium sulfate)
or buffer LC1X (20mM Tris, 10mm Hepes, 2.5mM magnesium sulfate, 20mM
ammonium sulfate and 5% glycerol) and 0.9U of AmpliTaq-Gold (Applied
Biosystems for Life Technologies, Monza, Italy). After polymerase activation for
10min at 951C, reactions were carried out for 30s at 951C, 1min at Tm (see
Supplementary Table S1) and 1min at 681C, for 30 cycles.
DHPLC analysis
We performed comparative mutation scanning to select amplicons for aberrant
DHPLC proﬁles not shared by the normal controls. DHPLC analysis was
performed on a WAVE DNA fragment analysis system (Transgenomic Inc.,
San Jose, CA, USA) equipped with a DNASep column (3500 High Throughput
(HT)) using a UV-C scanner to detect eluted DNA.27
mRNA extraction and cDNA preparation
We used a TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions to extract RNA from the muscle biopsies and the
PAXgene Blood RNA Kit (Qiagen, Hilden, Germany) to extract RNA from the
blood.28
The retrotranscription reaction was performed using 2mgo ft o t a lm R N A ,
according to the procedure described in the SuperScript III kit (Invitrogen).
RT-PCR and long PCR
We ampliﬁed the dysferlin cDNA in 13 overlapping fragments (Supplementary
Table S2). The reaction was performed in a ﬁnal volume of 25mlu s i n g1 mlo f
cDNA, 1mM of each primer, 2mM of dNTPs, Buffer JD1X,29 0.5U of LA-Taq
DNA polymerase (Takara BIO Inc.) and 1UI of Pfu polymerase (Stratagene,
Milan, Italy). Thermocycling was then carried out for 30s at 941C, 1.30min at
Tm (see Supplementary Table S2) and 2min at 681C, for 30 cycles.
Fragments were recovered from agarose gels by using the Mini Elute
Gel Extraction Kit (Qiagen) and then sequenced.
Sequencing
BigDye Terminator sequencing chemistry and ABI3130XL automatic DNA
sequencer (Applied Biosystems, Foster City, CA, USA) were used. Each
nucleotide change was veriﬁed by reverse sequencing and, in addition, by the
sequencing of an overlapping PCR product obtained with different primers.
Mutations were numbered on the basis of protein (GenBank NP_003485) and
cDNA sequence (GenBank NM_003494). Nucleotides were numbered accord-
ing to international recommendations.30–32
Array comparative genomic hybridization (CGH)
A custom array CGH (MotorChip 2.0) was developed using the Agilent 860K
( A g i l e n tT e c h n o l o g i e sI t a l i aS . p . A . ,M i l a n ,I t a l y )f o r m a t( S u r e P r i n tG 3a r r a y s ) .A l l
dysferlin exons, both the 5¢-a n d3 ¢-UTR, 2000bp at the 5¢ end of the gene (covering
the dysferlin promoter) were included. Probes were designed based on the exon and
ﬂanking intron sequences. Array CGH results were conﬁrmed by independent assays,
such as real-time PCR, long PCR and MLPA.
Bioinformatic software
Splice View software was useful to verify the effect of intronic variants on
mRNA splicing (http://bioinfo.itb.cnr.it/oriel/splice-view.html). Conservation
analysis was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/
index.html). To assess intronic and exonic mutations leading to splicing defects,
the Human Splicing Finder website (http://www.umd.be/SSF/) was consulted.33
RESULTS
To select patients with a Dysferlin deﬁciency from a heterogeneous
population of patients affected with an unclassiﬁed form of LGMD or
MM, we previously analysed muscle samples by a multiple WB. A
group of 65 patients who showed a marked reduction or absence of
Dysferlin were included in the study (Figures 1a and b). We excluded
cases having more than 20% Dysferlin, using a quantitative WB
assay.26 The average Dysferlin level was 5%±5. We combined different
screening methods to identify the causative alleles (Figure 1c).
From genomic DNA-DHPLC
D e s p i t et h ei n c o m p l e t eD H P L Cs e n s i t i v i t ya n dt h en o i s eo ft h ev a r i a n t s
and polymorphisms, this ﬁrst step was chosen for its cost-effectiveness.34
We screened by DHPLC and targeted a sequencing of all the 55 exons and
ﬂanking introns from the genomic DNA. DHPLC analysis was performed
on a ﬁrst group of 52 patients. We identiﬁed 47 causative mutations, 28
of which were new (Supplementary Table S3). A full molecular diagnosis
(both alleles) was provided for 35 out of 52 patients (67%).
mRNA analysis
We next performed mRNA analysis in cases without mutations or
with ambiguities (one allele, new mutations, possible splice defects
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European Journal of Human Geneticsand so on). We ﬁrst conﬁrmed the splice mutations on cDNA. We
also extended the analysis to an additional group of 13 patients.
Two sources of mRNA were considered: (1) skeletal muscle that,
when available, is the ﬁrst choice for the expression level and canonical
splicing of muscle dysferlin; (2) leukocytes that are easy to collect and
representative of non-muscle dysferlin, with some differences in the
alternative splicing of exons 5a, 17 or 40a.35,36 For this analysis, we
performed 16 muscle biopsies and, when not possible, collected blood
samples. The cDNA was ampliﬁed by PCR in 13 overlapping frag-
ments and then sequenced (Supplementary Figure S1). We identiﬁed
15 mutations, eight of which were novel. mRNA analysis was useful to
demonstrate the effect of two intronic variations on RNA splicing
(Figures 2a and b). Patient X311 carrying the homozygous mutation
906+4A4G showed a smaller ampliﬁcation product of fragment 3
(including approximately exons 7–12) of the dysferlin cDNA com-
pared with the control (Figure 2a). Direct sequencing showed that
exon 9 was skipped (Figure 2a). At the protein level, exon 9 skipping
causes the loss of a part of the C2B domain, important for the
protein function. Therefore, this variation should be considered as
pathological.
The transversion 1639-6T4A, found in a homozygosity state in
patient X389, inactivated the donor splice site (with the reactivation
of a new donor site in intron 18) resulting in retention of 4bp from
intron 18 sequence (Figure 2b) and a frameshift (Supplementary
Table S3).
Patient X546 (classiﬁed as having severe LGMD2B) showed o5%
Dysferlin. Molecular analysis conﬁrmed the presence of a frameshift
mutation, 1-bp deletion (g.2077delC) on exon 22 (Figure 2c) and the
heterozygous deletion of the entire exon 17 (Figure 2d). Exon
17 skipping did not affect the open reading frame, but the amino
acid at the exon junction changed (GAG4GTG, g.1481_1522del,
p.E494V+ex17skipping). The alternative splicing of the exon 17 had
previously been identiﬁed and characterized as blood cell isoform,36
but it had never been detected in the muscle.
DNA resequencing
All exon and ﬂanking intron resequencing was used to conﬁrm all the
mutations. We identiﬁed three additional mutations, the diagnosis
being completed in 58/65 patients (Table 1). Surprisingly, six appar-
ently homozygous alleles were not conﬁrmed by the DNA analysis.
These alleles were heterozygous, and for three out of six patients a
second nonsense mutation was identiﬁed in other regions of the gene.
This can be explained by the nonsense-mediated decay (NMD) of the
mRNA.16 (Figure 2e). For the other three patients with NMD, the
promoter region was not mutated.37
Array CGH, real-time PCR and long PCR
In all cases with an incomplete gene testing (0 or 1 mutated allele), we
performed a CGH array to identify possible heterozygous intragenic
rearrangements, such as deletions or duplications38 (Table 1). We used
a minimum of three probes per exon plus promoter probes covering a
genomic region of 220kb using a total of 196 probes. We identiﬁed
a heterozygous duplication involving the 5¢ end of the gene from exon
1 to 22 (3484), and a heterozygous deletion (X583). In addition, we
performed a long PCR on the mRNA and/or gDNA using primers
located at distant positions in the transcript in order to conﬁrm the
alterations.
Mutation spectrum
The exhaustive molecular analysis of the dysferlin gene led to the
identiﬁcation of 65 different mutations, 38 of which (60%) had not
previously been described (Supplementary Table S3 and Figure 3).
Thirty-one patients showed homozygous alleles (47.7%), most con-
ﬁrmed by segregation studies. Mutation scanning methods used in our
study led to the identiﬁcation of 19 additional novel non-pathological
variants (Supplementary Table S4). The present study conﬁrmed the
absence of a mutational hot-spot region as well as the spreading of
mutations along the entire gene. We detected 9 (14%) nonsense
mutations, 28 (43%) missense mutations, 5 (8%) splicing mutations,
Figure 1 Mutational scanning. (a) The picture shows the western blot on muscle lysate from patients (1 and 2) and control (c). As observed, patient 1
showed a complete absence of the dysferlin-speciﬁc band, whereas sample 2 shows a residual expression (5%) of dysferlin protein compared with the control
(as indicated by the arrow). (b) An exemplary image of a multiple western blot assay used in this study to screen and select the patients for further molecular
analyses (samples 1 and 2 show a complete dysferlin deﬁciency). For both a and b, the skeletal myosin bands in the post-transfer Coomassie blue staining
gels were used to normalize the amount of loaded protein. (c). The ﬂow chart shows the general design of the mutation analysis.
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European Journal of Human Genetics20 (30.5%) frame-shift mutations, 1 (1.5%) non-stop mutation and
2 (3%) large genomic rearrangements (Table 2).
For the novel mutations, their absence was demonstrated in 41000
control chromosomes from healthy individuals of matched ethnic
origin. In all 10 patients with 10–20% of Dysferlin, we always found at
least one missense mutation (100%), whereas among 24 patients with
0% Dysferlin a missense mutation was only found in 7 cases (29%).
DISCUSSION
The present study demonstrates that the marked reduction of Dys-
ferlin observed in LGMD/MM patients is not genetically hetero-
geneous. Given the location of Dysferlin, close to the muscle
membrane, its interactions with other proteins, and cumulative data
about the existence of secondary dysferlinopathies, this is surprising,
because in other membrane complexes, such as sarcoglycans, a
marked secondary reduction of each component is common. A
Dysferlin reduction has been observed in primary calpain-3 deﬁciency
(LGMD2A9) or Caveolin-3 deﬁciency (LGMD1C10). An LGMD/MM
phenotype has also been observed in patients carrying mutations in
the Anoctamin-5 gene (LGMD2L11).
Our results derive from an exhaustive analysis of RNA and DNA
from 65 patients having a severe Dysferlin reduction. In theory, it has
been claimed that a DNA analysis is necessary to diagnose a primary
dysferlinopathy.39 In practice, however, it is not easy. The dysferlin
gene is huge and composed of 55 exons. It spans 233140bp of
genomic DNA and generates a 6.9-kb-wide transcript. In our muta-
tion-screening ﬂowchart (Figure 1), the DNA analysis was ﬁrst carried
out by a DHPLC of all exons and ﬂanking introns. DHPLC is cheaper,
but it can produce false-negative/positive results and therefore it can
only have a screening value.40 A second problem with DHPLC is with
regard to the huge number of polymorphisms and variants that are
present in this gene (Supplementary Table S4). These are located in all
exons and confound an interpretation of the results with many
heteroduplex shifts per patient. We therefore used a second technique
based on the sequence analysis of the dysferlin cDNA. When a muscle
Figure 2 Elusive/peculiar mutations. (a) Exon 9 skipping in a patient with the variation 906+4A4G in homozygous state. RT-PCR products between DYSF
exons 7 and 12 showing the aberrantly spliced transcript. (a¢) Graphical presentation of the sequence composition of the wild-type transcript and the
aberrantly spliced transcript with the exon 9 skipping. (b) Partial intron 18 retention in a patient with the variation 1639-6T4A in homozygous state.
RT-PCR product sequencing between DYSF exons 12 and 19 showing a 4-bp retention of the intron 18, which is predicted to result in a truncated protein.
(c and d) Analysis of the cDNA sequence of patient X546 for (c) fragment 5 (including exon 22) and (d) fragment 4 (including exon 17). Both mutations
produce a frameshift. (e) Sequence analysis performed on speciﬁc fragments of dysferlin obtained from cDNA and DNA. The same mutation is shown for
both cDNA and DNA. The mutated nucleotide is highlighted in blue. All the patients showed the mutation in homozygous state on cDNA and heterozygous
state on DNA. The color reproduction of this ﬁgure is available on the html full text version of the manuscript.
Table 1 Number of causative alleles identiﬁed by the different
techniques
Mutations DHPLC DNA
mRNA
sequencing
gDNA
sequencing
Array CGH
real-time/long PCR
0 alleles 5 0 0 0
1a l l e l e 1 2 8 5 5
2 alleles 35 18 4 0
Samples examined 52 26 9 5
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European Journal of Human Geneticsbiopsy was not available, we were able to analyse the patients’ mRNA
from blood, as Dysferlin is highly expressed in the monocytes. This
method28,35 is less invasive and can provide an adequate amount of
mRNA: the analysis helped us to understand the pathogenic role of the
two intronic variants identiﬁed by DNA analysis, both leading to an
alteration of the splicing mechanism (Figures 2a and b).
Despite the larger number of cases identiﬁed by mRNA analysis,
this method alone can be faulty when the mutated allele is not
expressed. We showed that the mechanism of nonsense-mediated
mRNA decay (NMD) also occurred in dysferlinopathy.16 In six out
of 65 patients (Figure 2d) we identiﬁed a homozygous mutation in
cDNA, a mutation that was heterozygous in gDNA. By direct
sequencing of gDNA, we identiﬁed in 3/6 patients (X584, X674,
X676) an additional frameshift mutation that was missed by
DHPLC. For the three other patients (X267, X268, X675), we failed
to identify the primary cause of the missing mRNA expression of the
second allele; however, the NMD conﬁrmed the primary involvement
of the dysferlin gene.
This conﬁrms that mRNA analysis alone can be faulty, as true
homozygote patients cannot be distinguished from compound hetero-
zygote patients with important consequences in respect of genetic
counselling.
Third, we resequenced all the relevant genomic regions, and three
additional mutations were found. Furthermore, we used three addi-
tional methods: long PCR, real-time PCR and array CGH.
Particularly noteworthy was the ﬁrst evidence of a non-stop muta-
tion as a new pathological mechanism involved in the dysferlinopa-
thies. Patient X295 carries a homozygous 8-bp (g.6233_6240del,
p. P2078fsNON STOP) deletion that was identiﬁed in exon 55 of
the dysferlin gene. The deletion led to a frameshift in the reading
frame with the loss of the stop codon (Figures 4a and b). We supposed
that the new reading frame could give rise to the translation of 97
additional amino acids through the 3¢end of the mRNA. The patient
showed a residual expression of o10% of larger-sized Dysferlin in the
skeletal muscle (Figure 4c). We hypothesize that the mutation could
cause a mechanism of non-stop mRNA decay. Indeed, it was demon-
strated that in the eukaryotes there is a mechanism of degradation of
mRNA lacking the stop codon.41–44 Non-stop mutation has previously
been identiﬁed in the ACTA1 gene.45
Many groups have questioned the value of protein analysis in
carrying out a correct diagnosis. Fanin et al26 observed that the levels
of Dysferlin were reduced to 50% of those of the controls in the
carriers of LGMD2B. They showed that a reduction of 50% indicated
both familial and isolated LGMD2B heterozygotes, and suggested the
use of Dysferlin protein testing to select muscle biopsies from
suspected carriers for a subsequent mutation analysis.26
Our data support the dysferlin gene as the unique cause of Dysferlin
deﬁciency between 0 and 20% by WB analysis. Although for three
patients (3484, 4132 and X147) the second allele was not identiﬁed,
this was only because of incomplete testing for insufﬁcient DNA.
However, this does not affect the main conclusions of the study,
because these patients show sure causative alleles (frameshift/
duplication) that cannot be coincidental.
This marked reduction is necessary to affect muscle membrane
repair. We cannot exclude the presence of other functional mutations,
but a direct proof of pathogenicity is always required, as the dysferlin
gene shows a large number of variants and polymorphisms that can be
misleading. In these cases, the possible lack of mutations in the
dysferlin gene may be because of incomplete genetic testing.
The results obtained in this present paper have an immediate
diagnostic application: a Dysferlin reduction to 20% (which can also
be measured from blood monocytes28,35) can be used to identify
LGMD2B with 100% accuracy. In the case of LGMD2B this observa-
tion is noteworthy. When a rapid Dysferlin blood testing will be
available, important decisions will derive, such as to avoid steroids
(that are ineffective/deleterious in LGMD2B in contrast with other
forms of muscular dystrophy) and any distressing sport in children.7,46
Although it is generally agreed that an extensive molecular analysis
has a high cost, a precise determination of the dysferlin gene is,
however, particularly important from a diagnostic/counselling
Figure 3 Mutation spectrum. The picture shows the position of all the mutations identiﬁed in this study. identiﬁes missense mutations; identiﬁes
the frameshift (del/ins) mutation; identiﬁes the mutations affecting the splicing mechanism; identiﬁes the nonsense mutation.
Table 2 Classiﬁcation of all mutation types identiﬁed
(Het: heterozygote, Hom: homozygote)
Status
Class of mutation Mutations (%) Het Hom
Missense 28 (43%) 27 12
Nonsense 9 (14%) 9 5
Splice site 5 (8%) 2 5
Frameshift 20 (30.5%) 24 8
Non-stop 1 (1.5%) 0 1
Genomic rearrangements 2 (3%) 2 0
Numbers indicate how many mutation types were discovered.
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European Journal of Human Geneticsperspective and in view of the development of a future therapeutic
strategy. A successful recognition of all the mutations demonstrates
the power of a combined diagnostic strategy. More importantly, a
complete genetic testing should be applied to all other LGMD cases.47
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